Pear Therapeutics, Inc. (“Pear Therapeutics”), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs) , announced today the completion...
Pear Therapeutics, Inc. , the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore...
Pear Therapeutics, Inc. , the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it has received Breakthrough Device...
Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today provides an update on significant progress...
Today, Thimble Point Acquisition Corp, Inc. (NASDAQ: THMA) (“Thimble Point”), a special purpose acquisition company, Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing...
Pear Therapeutics, Inc. today announced the inclusion of Pear’s FDA-authorized prescription digital therapeutics (PDTs) reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update...
Pear Therapeutics, Inc. , the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, today announced management’s participation in the virtual BTIG...
Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing prescription digital therapeutics (“PDTs”) to treat serious disease , and Thimble Point Acquisition Corp. (“Thimble...
Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing prescription digital therapeutics (“PDTs”) to treat serious disease, and Thimble Point Acquisition Corp. (Nasdaq:...
NEW YORK, July 10, 2021 (GLOBE NEWSWIRE) --